Mechanism of IL-21 Protein in Tumor-Targeted Therapy

1. Research Background and Scientific Questions

The lack of functional tumor-infiltrating lymphocytes in the tumor microenvironment is a major reason for the suboptimal efficacy of tumor immunotherapy. Even in tumor tissues rich in tumor-infiltrating lymphocytes, the presence of dysfunctional PD-1-positive Tim-3-positive CD8-positive T cells remains a key indicator of poor prognosis in cancer patients. IL-21 protein, a 4α-helix bundle cytokine produced by CD4-positive T cells and natural killer T cells, can enhance the cytotoxicity of CD8-positive T cells and natural killer cells by stimulating their maturation, promote the differentiation of memory CD8-positive T cells, and suppress the production of regulatory T cells. However, the detailed mechanisms by which IL-21 protein influences dysfunctional CD8-positive T cell subsets in tumors remain unclear, and its short half-life also limits clinical applications.

2. Tumor-Targeted Delivery Strategy for IL-21 Protein

By analyzing The Cancer Genome Atlas database, researchers found that high expression of IL-21 protein in the tumor microenvironment of skin melanoma and head and neck squamous cell carcinoma patients is positively correlated with improved survival rates. To investigate whether the IL-21-mediated antitumor effect occurs within the tumor, researchers compared the therapeutic efficacy of local intratumoral injection and systemic intraperitoneal injection of IL-21-Fc fusion protein. They found that local delivery, but not systemic administration, effectively controlled tumor growth. Based on this, the researchers designed a cetuximab-IL21 fusion protein that directly binds to cEGFR-positive tumor cells, enabling precise tumor-targeted delivery of IL-21 protein. Experiments confirmed that this fusion protein specifically targets cEGFR-positive tumor cells and effectively inhibits tumor growth.

3. Comparison of Antitumor Effects Between IL-21 and IL-2 Proteins

At the same dose, tumor-targeted IL-21 fusion protein and IL-2 fusion protein exhibited similar antitumor effects, but the IL-21 fusion protein showed lower in vivo toxicity. IL-2 fusion protein treatment caused significant weight loss in mice and even death at high doses, while the same dose of IL-21 fusion protein had no obvious effect on mouse weight, and the treated mice maintained high long-term survival rates. This finding suggests that IL-21 fusion protein is a safe and effective tumor-targeted therapeutic molecule.

4. CD8-Positive T Cell-Dependent Antitumor Mechanism of IL-21 Protein

To explore the immune cell basis of IL-21 protein's antitumor effects, researchers depleted natural killer cells, macrophages, CD4-positive T cells, and CD8-positive T cells separately. The results showed that only the depletion of CD8-positive T cells abolished the antitumor effect of the IL-21 fusion protein. Flow cytometry analysis confirmed that IL-21 fusion protein treatment significantly increased the proportion and functionality of tumor-infiltrating CD8-positive T cells. Further studies revealed that pre-existing tumor-infiltrating CD8-positive T cells are crucial for IL-21 therapy, rather than newly migrated CD8-positive T cells. IL-21 treatment also established memory T cell-mediated antitumor responses, limiting the growth of distal tumors.

5. Regulatory Role of IL-21 Protein on CD8-Positive T Cell Subsets

Researchers divided antigen-specific CD8-positive T cells into three groups based on PD-1 expression levels: high, moderate, and absent. IL-21 treatment reduced the mean fluorescence intensity of PD-1 in antigen-specific CD8-positive T cells, an effect not due to new infiltrating cells. Further research found that IL-21 protein selectively proliferates PD-1 moderately expressed Tim-3-negative functional CD8-positive T cells, expanding the functional tumor-infiltrating T cell population and limiting the development of exhausted T cells in the tumor microenvironment. In tumor cells, PD-1 moderately expressed Tim-3-negative CD8-positive T cells are more functional than PD-1-positive Tim-3-positive CD8-positive T cells, suggesting that IL-21's antitumor activity primarily depends on the expansion of this specific T cell subset.

6. Synergistic Effects of IL-21 Protein and Immune Checkpoint Blockade

The study found that after initial treatment with IL-21 fusion protein, PD-L1 expression was upregulated in dendritic cells and macrophages. Based on this finding, researchers hypothesized that blocking the interaction between PD-1 and PD-L1 might enhance the therapeutic effect of IL-21. Experiments confirmed that compared with either monotherapy, the combination of IL-21 fusion protein and anti-PD-L1 significantly enhanced tumor growth inhibition in tumor-bearing mice and prolonged their survival. This synergistic effect provides a new strategy for the treatment of advanced tumors.

7. Research Significance and Future Perspectives

This study successfully extended the half-life and improved the antitumor efficacy of IL-21 protein by designing a tumor-targeted IL-21 fusion protein. The research redefined the key mechanism by which IL-21 protein exerts its antitumor effects by promoting the proliferation of specific CD8-positive T cell subsets and reducing dysfunctional CD8-positive T cells in the tumor microenvironment. The synergistic effect of IL-21 fusion protein and immune checkpoint blockade provides new insights for enhancing antitumor immune responses. As a cytokine with antitumor potential, the application value of IL-21 protein in tumor-targeted delivery and combination therapy warrants further exploration.

8. Which Manufacturers Provide IL-21 Protein?

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed "IL-21 Protein, Human", a high-quality recombinant protein reagent specifically designed for the functional regulation of T cells, B cells, NK cells, and immunotherapy research. This protein is human interleukin-21 (IL-21), an important member of the γc family of cytokines. It efficiently activates the IL-21 receptor signaling pathway, promotes T cell proliferation and differentiation, B cell differentiation into plasma cells, and enhances NK cell cytotoxicity, providing a stable and reliable standardized tool for tumor immunotherapy, autoimmune disease mechanism exploration, and vaccine development.

Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug research. For detailed technical parameters, validation data, or specific application inquiries regarding "IL-21 Protein, Human" (Catalog No.: UA040009), please feel free to contact us.